Cure Ventures, a Boston, MA-based life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, appointed industry leaders Jeff Jonas, M.D. and Al Robichaud, Ph.D. as partners.
The move enables the firm to expand its work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
Most recently, Dr. Jonas was the chief executive officer (CEO) of the incubation platform, ABio-X. He was previously the CEO of Sage Therapeutics, where he developed several advances in central nervous system treatments. Millions of people across the globe may have been potentially helped by drugs where Dr. Jonas has led organizations and teams responsible for the development and support of medicines such as Mirapex, Lexapro, Vyvanse, Zulresso, Zurzuvae and Namenda.
Dr. Jonas has a long history of accelerating growth as evidenced by Sage’s $3 billion alliance with Biogen. A graduate of Harvard Medical School, he has also served as president of Shire Regenerative Medicine, executive vice president of Ionis Pharmaceuticals and chief medical officer of Forest Laboratories.
Al Robichaud, Ph.D., former Chief Scientific Officer at Sage, will help the firm solidify its leadership team as Cure Ventures prepares for new ventures in 2024 and beyond. A Ph.D. recipient in organic chemistry from UC Irvine, Robichaud brings more than 35 years of experience. While at Sage, Robichaud helped launch the company into the public market, and oversaw the discovery and development of two commercially approved drugs, Zulresso and Zurzuvae. He also is the primary discovery scientist, and principal inventor of Caplyta, an approved drug for the treatment of bipolar depression. Prior to Sage, Robichaud held multiple leadership roles at large pharmaceutical companies focused primarily on neuroscience.
Founded in 2021 by Richard (Rich) Lim, M.B.A.; David (Dave) Fallace, J.D., M.B.A.; and Lou Tartaglia, Ph.D., Cure Ventures is a life sciences venture capital firm focusing on de novo company formation around groundbreaking curative technologies. Its investment thesis is founded on three tenets:
- A seed funding model;
- genetic validation that increases the probability of success; and
- embedded operators to drive the best day-to-day decision making in collaboration with founders.